83 related articles for article (PubMed ID: 21475131)
41. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
[TBL] [Abstract][Full Text] [Related]
42. Carboplatin-induced alteration of the thiol homeostasis in the isolated perfused rat kidney.
Giustarini D; Dalle-Donne I; Paccagnini E; Milzani A; Rossi R
Arch Biochem Biophys; 2009 Aug; 488(1):83-9. PubMed ID: 19531364
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
44. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
45. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
46. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
47. Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting.
Mazumdar M; Smith A; Tong WP; Motzer RJ
J Natl Cancer Inst; 2000 Sep; 92(17):1434-6. PubMed ID: 10974080
[No Abstract] [Full Text] [Related]
48. Difficulties in carboplatin dosage due to different methods of serum creatinine determination.
Groth G; Gatzemeier U
Lung Cancer; 2002 Oct; 38(1):97-8. PubMed ID: 12367800
[No Abstract] [Full Text] [Related]
49. Variability of carboplatin dose calculation methods in Spain.
Cuesta-Grueso C; Burgos-San José A; Cajaraville-Ordoñana G; Poquet-Jornet JE; Mangues-Bafalluy I; Díaz-Carrasco MS
J Oncol Pharm Pract; 2019 Oct; 25(7):1551-1557. PubMed ID: 30176785
[TBL] [Abstract][Full Text] [Related]
50. Carboplatin and renal function.
Smit EF; Sleijfer DT; Meijer S; Mulder NH; Postmus PE
Ann Intern Med; 1989 Jun; 110(12):1034. PubMed ID: 2658713
[No Abstract] [Full Text] [Related]
51. Carboplatin in elderly patients.
Sorio R; Talamini R; Toffoli G; Lombardi D; Libra M; Veronesi A
Tumori; 2002; 88(1 Suppl 1):S35-6. PubMed ID: 11989919
[No Abstract] [Full Text] [Related]
52. Chemotherapy dosing part II: alternative approaches and future prospects.
Kaestner SA; Sewell GJ
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):99-107. PubMed ID: 17355104
[TBL] [Abstract][Full Text] [Related]
53. Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers.
Cartwright D; White M; Crearie C; Forte C; Coulter S; Brown J; Randhawa M; Glasspool R; Roxburgh P
ESMO Open; 2022 Aug; 7(4):100533. PubMed ID: 35870374
[No Abstract] [Full Text] [Related]
54. Response to the letter entitled "Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers".
Samani A; Krell J; McNeish I; Tookman L
ESMO Open; 2022 Aug; 7(4):100534. PubMed ID: 35841803
[No Abstract] [Full Text] [Related]
55. Improving Carboplatin Dosing Based on Estimated GFR.
Beumer JH; Inker LA; Levey AS
Am J Kidney Dis; 2018 Feb; 71(2):163-165. PubMed ID: 29217306
[No Abstract] [Full Text] [Related]
56. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs?
Aamdal S
Ann Oncol; 1992 Nov; 3(9):774. PubMed ID: 1450070
[No Abstract] [Full Text] [Related]
57. [Cardiac toxicity by carboplatin].
Gómez M; Villuendas R; Serés L; Valle V
Med Clin (Barc); 2003 Oct; 121(11):436. PubMed ID: 14563278
[No Abstract] [Full Text] [Related]
58. Cancer and the kidney: individualizing dosage according to renal function.
Launay-Vacher V
Ann Oncol; 2013 Nov; 24(11):2713-4. PubMed ID: 24170609
[No Abstract] [Full Text] [Related]
59. Further refinement of carboplatin dosing.
Egorin MJ
J Natl Cancer Inst; 1995 Apr; 87(8):555-7. PubMed ID: 7752248
[No Abstract] [Full Text] [Related]
60. Flashback Foreword: Carboplatin Dosage Based on Renal Function.
Maki RG; Cannistra SA
J Clin Oncol; 2023 Oct; 41(28):4451-4452. PubMed ID: 37757591
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
